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We previously showed that the tumor 
suppressor gene REIC/Dkk-3, when 
overexpressed by an adenovirus 
(Ad-REIC), exhibited a dramatic 
therapeutic effect on human cancers 
through a mechanism triggered by ER 
stress. Adenovirus vectors show no target 
cell specificity and thus may elicit 
unfavorable side effects through infection 
of normal cells even upon intra-tumoral 
injection. In the present study, we 
examined possible effects of Ad-REIC on 
normal cells. We found that infection of 
normal human fibroblasts (NHF) did not 
cause apoptosis but induced production of 
IL-7. The induction was triggered by ER 
stress and mediated through IRE1α, 
ASK1, p38, and IRF-1. When 
Ad-REIC-infected NHF were 
transplanted in a mixture with untreated 
human prostate cancer cells, the growth 
of the cancer cells was significantly 
suppressed. Injection of an IL-7 antibody 
partially abrogated the suppressive effect 
of Ad-REIC-infected NHF. These results 
indicate that Ad-REIC has another arm 
against human cancer, an indirect 
host-mediated effect due to 
overproduction of IL-7 by mis-targeted 
NHF, in addition to its direct effect on 
cancer cells. 
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  Cancer cells, like normal cells, cannot 
be free from regulation by other cells in the 
body (1). The microenvironment can exert 
both promotive and suppressive effects on 
malignant cells (2). The embryonic 
environment has been shown to suppress 
malignant phenotypes (3,4), and the 
mechanism was recently indicated to be 
suppression of Nodal function by Lefty (5).  
Cells comprising cancer stroma in adult 
tissues are also involved in tumor 
suppression (6,7). Mobilization of such 
potential tumor-suppressive effects of the 
microenvironment would provide an 
additional arm for cancer therapy (8).  
 Adenovirus vectors combined 
with appropriate cargo genes have great 
potential in cancer gene therapy because of 
their high infection efficiency and marginal 
genotoxicity (9). However, they show no 
target cell specificity and thus may also 
infect normal cells present in the 
surroundings of cancer cells. Provided that 
the interaction between cancer cells and 
normal cells is relevant to 
progression/suppression of cancer, it is 
critically important to understand not only 
cell autonomous phenomena in individual 
cell types infected by a therapeutic virus 
vector but also potential effects of the 
therapeutic virus vector on the composite 
system of interacting cell populations.  
We have been studying the possible 
utility of an adenovirus vector carrying the 
tumor suppressor gene REIC/Dkk-3 
(Ad-REIC) for gene therapy against human 
cancer. REIC/Dkk-3 was first identified as a 
gene that was down-regulated in association 
with immortalization of normal human 
fibroblasts (NHF) (10). Expression of 
REIC/Dkk-3 gene was shown to be reduced 
in many human cancer cells and tissues, 
including prostate cancer, renal clear cell 
carcinoma, testicular cancer, and non-small 
cell lung cancer (11- 14), probably due to 
hyper-methylation of the promoter (15). A 
single injection of Ad-REIC into tumors 
formed by transplantation of human prostate 
cancer cells (PC3 cells) into mice resulted in 
4 out of 5 mice becoming tumor-free (13). 
Subsequently, we found that Ad-REIC was 
effective also for human cancers derived 
from the testis, pleura, and breast (14,16,17). 
The potent multi-targeting anti-cancer 
function of Ad-REIC shows great promise 
for clinical application, which will be 
shortly initiated. 
 REIC/Dkk-3 is a highly-glycosylated 
secretory protein and considered to 
physiologically act on cells via a 
yet-unidentified receptor. However, we 
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found that the induction of apoptosis in 
cancer cells by Ad-REIC was due to 
endoplasmic reticulum (ER) stress loaded by 
overproduction of REIC/Dkk-3 protein and 
that exogenously applied REIC/Dkk-3 
protein showed no apoptosis-inducing 
activity for cancer cells (13,14). Activation 
of c-Jun N-terminal kinase (JNK) was 
shown to be an essential step for the 
induction of apoptosis by Ad-REIC. ER 
stress is evoked by overload of 
unfolded/misfolded proteins in the ER, and 
eukaryotic cells respond to the threat by 
activating an unfolded protein response, i.e., 
attenuating de novo protein synthesis, 
promoting protein degradation by 
proteasomes, and inducing chaperone 
proteins to help proper folding of proteins 
(18). When ER stress remains at a level 
manageable by the unfolded protein 
response, cells can survive. On the other 
hand, overload of unfolded/misfolded 
protein beyond the cellular adoptive 
response leads to apoptotic cell death. While 
Ad-REIC strongly induces apoptosis in 
many types of cancer cells, normal cells thus 
far examined are resistant to 
Ad-REIC-induced apoptosis despite 
expression of REIC/Dkk-3 at a level similar 
to that in cancer cells (13). The aim of the 
present study was to determine the 
mechanisms of differential response of 
normal cells and cancer cells to Ad-REIC 
and to reveal the possible effect of Ad-REIC 
on a composite interacting system of normal 
cells and cancer cells. We found that 
Ad-REIC induced NHF to produce IL-7 via 
ER stress-triggered activation of p38. 
Furthermore, Ad-REIC-infected NHF 
significantly suppressed tumor growth of 
untreated PC3 cells transplanted in a mixture 
in vivo. These results mean that, in addition 
to its direct cancer cell-killing activity, 
Ad-REIC has another mechanism of action 
against human cancer, an indirect 
host-mediated effect due to overproduction 
of IL-7 by mis-targeted NHF. 
 
Experimental Procedures 
 
Cells and chemicals- The human prostate 
cancer cell line PC3 and the mouse colon 
cancer cell line Colon26 were cultivated in 
HAM’S F-12 K medium and RPMI1640, 
respectively, supplemented with 10% FBS. 
Normal human fibroblasts (OUMS-24), 
which were established and provided by Dr. 
Namba et al. (19), and primary mouse 
dermal fibroblasts were cultured in 
Dulbecco’s modified MEM (Nissui, Tokyo, 
Japan) with 10% FBS. REIC/Dkk-3 protein 
was purified from the conditioned medium 
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of Ad-REIC-infected NHF by two-step 
ion-exchange column chromatography. p38 
inhibitors (SB203580 and SC68376) and a 
PKB/Akt inhibitor (Akt inhibitor) were 
purchased from Calbiochem (La Jolla, CA). 
A JNK inhibitor (SP600125) and  
tunicamycin from Streptomyces sp. were 
purchased from Biomol (Plymouth Meeting, 
PA) and Sigma (St Louis, MO), respectively. 
Human recombinant IL-7, a neutralizing 
mouse-antibody against human IL-7, and 
mouse control IgG were from Peprotech EC 
(London, England). Human recombinant 
IL-7 was purchased from Peprotech EC. 
Adenovirus vectors- REIC/Dkk-3 was 
overexpressed using an adenovirus (13). 
Ad-LacZ was used as a control. 
Western blot analysis- Western blot analysis 
was performed under conventional 
conditions. Antibodies used were as follows: 
rabbit anti-human REIC/Dkk-3 antibody 
raised in our laboratory; mouse 
anti-β-galactosidase antibody (Calbiochem); 
rabbit anti-human IRF-1, rabbit anti-human 
SAPK/JNK, mouse anti-human 
phospho-SAPK/JNK (Thr183/Tyr185), 
rabbit anti-human c-Jun, rabbit anti-human 
phospho-c-Jun (Ser63), rabbit anti-human 
phospho-STAT1 (Ser727), rabbit anti-human 
phospho-STAT1 (Tyr701), rabbit anti-human 
p38, rabbit anti human phospho-p38 
(Thr180/Tyr182), rabbit anti-human ASK1, 
rabbit anti-human phospho-ASK1 (Thr845), 
and rabbit anti-human IRE1α antibodies 
(Cell Signaling Technology, Beverly, MA); 
rabbit anti-human phospho-IRE1α (Ser724) 
antibody (ABR, Golden); rabbit anti-human 
IRF-2 antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA); rabbit anti-human STAT1 
antibody (Abcam, Cambridge, MA); and 
mouse anti-human tubulin antibody (Sigma). 
The second antibody was 
horseradish-peroxidase-conjugated 
anti-mouse or anti-rabbit IgG antibody (Cell 
Signaling Technology). Positive signals 
were detected by a chemiluminescence 
system (ECL plus, GE Healthcare 
Bio-Sciences, Piscataway, NJ). 
Detection of IL-7 production- Screening for 
cytokines produced by NHF infected with 
Ad-REIC was carried out by using RayBio 
Human Cytokine Antibody Array VI & 6.1 
(RayBiotech, Norcross, GA). NHF were 
infected with either Ad-LacZ or Ad-REIC 
(20 MOI) and cultured for 48 h in 
serum-free Dulbecco's modified MEM. The 
medium incubated for the last 24 h was used 
for the assay. ELISA was performed using 
an assay kit (Human IL-7 ELISA Kit: 
RayBiotech). 
Northern blot analysis- Twenty micrograms 
of total RNA isolated by the acid 
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guanidinium thiocyanate/phenol-chloroform 
method was electrophoresed in a 1% agarose 
gel and transferred to a Nytran Plus nylon 
membrane (GE Healthcare Bio-Sciences). A 
part of the human IL-7 gene (534-bp 
fragment) amplified by PCR using a primer 
set (forward: 
5’-ATGTTCCATGTTTCTTTTAG-3’ and 
reverse: 3’- 
TCAGTGTTCTTTAGTGCCCA-5’) was 
used as a probe. 
Chromatin immunoprecipitation- Chromatin 
immunoprecipitation was performed under 
conventional conditons. In brief, cells were 
treated with 1% formaldehyde for 
cross-linking. Rabbit antibodies against 
human IRF-1 and IRF-2 were obtained from 
Santa Cruz Biotechnology. To amplify the 
IRF-responsive region of the IL-7 promoter 
(381 bp; –539 to -158), a forward primier 
(5’-ACTTGTGGCTTCCGTGCACACATT-
3’) and a reverse primer 
(3’-GACTGCAGTTTCATCCATCCCAAG-
5’) were used. 
 Pull-down of proteins bound to the IL-7 
promoter in vitro- Pull-down assay of 
proteins bound to the IL-7 promoter was 
performed under conditions reported 
previously (20). Briefly, the biotinylated 
genomic fragment (–1345 to -9) of the 
human IL-7 promoter was incubated with 
nuclear extracts and pulled down using a 
streptavidine agarose (Invitrogen, Carlsbad, 
CA). Bound proteins were determined by 
Western blot analysis. 
RNA interference- Small interfering RNAs 
(siRNAs) against human IRF-1 and Stat1 
cDNAs (pre-designed siRNA for IRF-1, ID# 
144970, and validated siRNA for Stat1, ID# 
42860) and control siRNA (Silencer 
Negative control 2 siRNA) were purchased 
from Ambion (Austin, Texas).  IRE1α 
siRNA (siGENOME SMART pool 
M-004951) was purchased from Thermo 
Scientific Dharmacon (Lafayette, CO). 
Transient transfection of siRNAs was 
performed using lipofectamine 2000 
(Invitrogen) 24 h prior to infection with 
Ad-LacZ or Ad-REIC. 
Monitoring of tumor growth in vivo- PC3 
cells either alone or with NHF (5x106 cells 
each) were subcutaneously transplanted into 
male BALB/C nu/nu mice (SLC, 
Hamamatsu, Japan). The cells were infected 
with Ad-REIC or Ad-LacZ 24 h prior to 
transplantation at 20 MOI. The size of 
tumors was measured with a vernier caliper 
and tumor volume was calculated as 1/2 x 
(shortest diameter)2 x (longest diameter). 
Anti-human IL-7 neutralizing antibody (0.5 
mg) was intraperitoneally injected on day 0 
(prior to cell transplantation) and on day 4. 
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For the assay in immune-competent mice, 
untreated Colon26 cells (4x106) mixed with 
dermal fibroblasts (4x106) infected with 
either Ad-LacZ or Ad-REIC at 100 MOI 
were subcutaneously transplanted into 
6-week-old female BALB/c mice.  
 For in vivo imaging of tumor growth, 
PC-3M-luc-C6 Bioware cells (PC3-luc; 
Caliper Life Sciences, Hopkinton, MA) and 
OUMS-24 cells were infected with either 
Ad-REIC or Ad-LacZ in DME/F12 medium 
with 10% FBS 24 h prior to transplantation.  
A cell suspension (100 μl) containing 3x106 
cells of each type was mixed with Matrigel 
(100 μl; BD Biosciences) and injected into 
the right flank subcutis of 8-week-old nude 
mice. Tumor size was monitored after 
injection with Beetle Luciferin potassium 
salt (Promega) using IVIS 2000 (Xenogen, 
Alameda, CA). 
Assay of splenic NK cell activity- Spleen 
cells were isolated from tumor-bearing nude 
mice and NK cells were enriched using a 
mouse NK cell isolation kit (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Cytotoxicity 
of NK cells to PC3 was determined using a 
Cytox96 Non-radioactive Cytotoxicity 
Assay (Promega, Madison, WI) under 
conditions recommended by the 
manufacturer. Briefly, the effector NK cells 
and the target PC3 cells (5,000 cells/well) 
were inoculated at ratios of 100:1, 50:1, 25:1, 
and 12.5:1 and incubated for 4 h at 37OC. 
Activity of lactate dehydrogenase released 
from the cells was quantitated. 
Statistical analysis- Prior to statistical 
analysis, each experiment was repeated at 
least three times.  The results are expressed 
as means +/- SD.  Statistical analysis was 
performed by Student's t test.  P values of 
less than 0.05 were considered statistically 
significant. 
 
RESULTS 
 
 Induction of IL-7 in NHF by infection 
with Ad-REIC. As reported previously (13), 
Ad-REIC efficiently induced apoptosis in 
PC3 cells (Fig. 1A). NHF did not undergo 
apoptosis but survived despite the fact that 
infection with Ad-REIC resulted in 
expression of REIC/Dkk-3 at a level similar 
to that in PC3 cells (Fig. 1B and 
supplemental Fig. S1A). Confluent NHF 
continuously overexpressed REIC/Dkk-3 
protein for up to 2 weeks when infected with 
Ad-REIC (Fig. 1C). No gross alteration in 
morphology or behavior of NHF caused by 
Ad-REIC was noted.  
 We screened for possible production 
of a humoral factor or factors by 
Ad-REIC-infected NHF. Application of a 
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cytokine profiler array to the conditioned 
medium of Ad-REIC-infected NHF resulted 
in identification of IL-7 (Fig. 1D). 
Antibodies against other cytokines/growth 
factors carried by the array, including those 
against IL-1~6, -10, -13, -15 and -17, TNFα, 
and interferon γ gave negative results.  
Infection of NHF with Ad-REIC induced 
IL-7 mRNA in culture (Fig. 1E). The 
infected NHF secreted IL-7 into the culture 
medium, ~35 pg/ml/104 cells/48 h, while 
NHF infected with an adenovirus carrying 
LacZ (Ad-LacZ) produced no appreciable 
amount of IL-7 (Fig. 1F).  
 Induction of IL-7 in NHF by Ad-REIC 
was triggered by ER stress and mediated by 
ASK1 and p38. REIC/Dkk-3 is a secretory 
protein that is assumed to act on cells via a 
yet-unidentified cell surface receptor. On the 
other hand, we concluded from the results of 
previous work that apoptosis in 
Ad-REIC-infected cancer cells was triggered 
by ER stress (13,14). As shown in Fig. 2A, 
infection of NHF with Ad-REIC induced 
IL-7 mRNA in culture, while exogenous 
REIC/Dkk-3 protein highly purified from 
the conditioned medium of NHF infected 
with Ad-REIC (supplemental Fig. S1B) 
showed no effect on IL-7 mRNA level, 
indicating that induction of IL-7 by 
Ad-REIC depends on intracellular 
production of REIC/Dkk-3 and not on 
secreted REIC/Dkk-3 protein per se. In 
accordance with this, tunicamycin, a 
representative inducer of ER stress, induced 
IL-7 in NHF (Fig. 2B), and down-regulation 
of a ER stress sensor, IRE1α, resulted in 
complete abrogation of the induction of IL-7 
by Ad-REIC as well as tunicamycin (Fig. 
2C). We therefore examined ER stress and 
its downstream pathway in NHF and PC3 
cells.  
 IRE1αwas activated in both NHF and 
PC3 cells upon infection with Ad-REIC (Fig. 
2D). ASK1 was reported to be recruited to 
and phosphorylated by IRE1α on the ER 
membrane when cells suffer from ER stress 
(21). Activated ASK1, one of the 
MAPKKKs, in turn activates JNK and p38 
by phosphorylation via MAPKK4/MAPKK7 
and MAPKK3/MAPKK6, respectively. We 
therefore examined functional state of the 
signal transduction pathway in 
Ad-REIC-infected NHK and PC3 cells. 
Activation of JNK, a hallmark for the 
induction of apoptosis by Ad-REIC (13,14), 
was observed in PC3 cells but not in NHF as 
demonstrated by phosphorylation of JNK 
and its substrate c-Jun (Fig. 2D). 
Constitutive p38 level was higher in PC3 
cells than in NHF. Infection with Ad-REIC 
induced phosphorylation of p38 in both cell 
7 
types. Thus, infection with Ad-REIC 
provoked ER stress in a similar manner in 
NHF and PC3 cells at initial stages but 
resulted in distinct activation profiles of key 
stress-mediator MAPKs. In contrast to the 
effect of Ad-REIC, application of 
tunicamycin resulted in activation of both 
JNK and p38 in NHF (Fig. 2E). p38 
inhibitors, SB203580 and SC68376, but not 
inhibitors for JNK and Akt, abrogated 
induction of IL-7 in NHF by Ad-REIC (Fig. 
2F).These results indicate that activation of 
p38 is a critical event for the induction of 
IL-7 by Ad-REIC. 
 IRF1 is a critical transacting factor 
for the induction of IL-7 in NHF infected 
with Ad-REIC. Although various types of 
cells have been shown to produce IL-7, little 
is known about the regulation of IL-7 gene 
expression (22). IRF-1 and IRF-2 are among 
a few transcription factors that have been 
reported to act on the IL-7 promoter in cells 
exposed to interferon γ or ultraviolet (23,24).  
We therefore examined possible 
involvement of IRF-1 and IRF-2 in the 
induction of IL-7 by Ad-REIC. IRF-1 was 
induced in NHF but not in PC3 cells by 
Ad-REIC, while IRF-2 was constitutively 
expressed in both types of cells (Fig. 3A). A 
pull-down assay for proteins bound to the 
IL-7 promoter resulted in identification of 
IRF-1 and IRF-2 (Fig. 3B). IRF-2 was 
fished with a probe of the IL-7 promoter in 
the nuclear extracts of untreated and 
Ad-LacZ-treated NHF, which was replaced 
by IRF-1 in the nuclear extract of 
Ad-REIC-infected NHF. This observation 
was corroborated by the results of an 
electromobility shift assay shown in Fig. 3C. 
The probe was supershifted by an IRF-1 
antibody in NHF upon infection with 
Ad-REIC, while incubation with an IRF-2 
antibody resulted in supershift of the probe 
in the control cells and in partial shift-down 
of the band in Ad-REIC-infected NHF, this 
being probably due to binding of IRF-1 to 
the probe. Chromatin immunoprecipitation 
confirmed that the interaction of IRF-1 and 
IRF-2 on the IL-7 promoter took place in 
NHF in a manner similar to that observed in 
vitro (Fig. 3E). These results suggests 
involvement of IRF-1 in the induction of 
IL-7 triggered by ER stress on infection of 
NHF with Ad-REIC. To examine functional 
significance of the binding of IRF-1 on the 
promoter of IL-7, we applied siRNA of 
IRF-1 to NHF prior to Ad-REIC infection. 
The down-regulation of IRF-1 (Fig. 3D) not 
only abrogated induction of IL-7 by 
Ad-REIC in NHF but also suppressed the 
constitutive low expression level of IL-7 
(Fig. 3F). These results indicate that in 
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non-stimulated NHF IRF-2 is constitutively 
expressed and negatively regulates the IL-7 
gene by binding to the promoter and that 
IRF-1 is induced upon infection with 
Ad-REIC and activates the IL-7 gene by 
expelling IRF-2 from the IL-7 promoter.  
 STAT1 links p38 and IRF-1. The next 
question was how IRF-1 was induced in 
Ad-REIC-infected NHF. Li et al. (25) 
reported that STAT1 homodimer or 
STAT1/STAT2 heterodimer transcriptionally 
activated IRF-1 in cells exposed to 
interferon α.  On the other hand, STAT1 
has been shown to be activated through 
phosphorylation by p38 (26). We therefore 
examined the possibility that STAT1 may 
link p38 and IRF-1 in the signal transduction 
pathway for the induction of IL-7 by 
Ad-REIC in NHF. Application of p38 
inhibitors, SB203580 and SC68376, but not 
inhibitors for JNK and Akt, inhibited 
phosphorylation of STAT1 and induction of 
IRF-1 (Fig. 4A). SB203580 and SC68376 
inhibit activity of p38, i.e., phosphorylation 
of p38 substrate proteins, but do not inhibit 
activation of p38, i.e., phosphorylation of 
p38 protein itself (supplemental Fig. S2C). 
In the present settings, phosphorylation of 
Ser727 and not Tyr701 of STAT1 is critical 
for the induction of IRF-1 (Fig. 4F). 
Down-regulation of STAT1 using siRNA 
resulted in abrogation of the induction of 
IRF-1, but not the activation of upstream 
p38, in NHF infected with Ad-REIC (Fig. 
4B). The abortive induction of IRF-1 
resulted in reoccupation of the IL-7 
promoter by IRF-2 and eventually in 
abrogation of induction of IL-7 in NHF 
infected with Ad-REIC (Figs. 4C and 4D). 
Exogeneous IL-7 did not induce IL-7 itself 
nor activate the p38-STAT1-IRF-1 pathway 
(Figs. 4E and 4F). These results collectively 
indicate that IL-7 was induced by Ad-REIC 
in NHF via the pathway summarized in Fig. 
4E.  
 Suppression of tumor growth by NHF 
infected with Ad-REIC. IL-7 is known to 
play a crucial role in development and 
survival of lymphocytes (22) and has been 
exploited for potential clinical application 
(27-29).  Miller et al. (30) reported that 
IL-7-transduced dendritic cells evoked 
systemic immune responses and exerted a 
potent anti-tumor effect in a murine lung 
cancer model. We therefore examined the 
possible effect of infection of NHF with 
Ad-REIC on the composite interacting 
system of normal and cancer cells. When 
PC3 cells mixed with NHF pre-infected with 
Ad-REIC were transplanted into nude mice, 
growth of the PC3 cells was significantly 
suppressed compared with that in the case of 
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transplantation of NHF infected with 
Ad-LacZ (Fig. 5A and supplemental Fig. 
S3A). Histological analysis of the tumors 
revealed decomposed tissue with 
degenerated PC3 cells when transplanted 
with Ad-REIC-infected NHF and a solid 
tissue packed with viable PC3 cells when 
transplanted with Ad-LacZ-infected NHF 
(Fig. 5B). The characteristics of 
tumor-stoma cells may differ from those of 
normal human fibroblasts. We therefore 
performed an experiment similar to that 
shown in Fig. 5A using human lung 
cancer-associated cells and obtained similar 
results (supplemental Fig. S3B). The tumor 
suppressive effect of Ad-REIC-infected 
normal mouse fibroblasts was also observed 
in immune-competent BALB/c mice into 
which syngeneic colon cancer cells 
(Colon26) had been transplanted (Fig. 5C 
and supplemental Fig. S3C). For monitoring 
the growth of the cancer cells specifically, 
we transplanted a mixture of NHF and PC3 
cells transduced with the luciferase gene 
(PC3-luc) and observed them with IVIS 
2000 (Fig. 5D). Partial suppression of tumor 
growth in vivo was observed when PC3-luc 
was infected with Ad-REIC at 1 MOI prior 
to transplantation. Co-transplantation of 
PC3-luc with Ad-REIC-infected NHF (20 
MOI) synergistically suppressed the growth 
of PC3-luc compared with that with 
Ad-LacZ-infected NHF. On the other hand, 
co-cultivation of PC3 cells with 
Ad-REIC-infected NHF affected neither 
apoptotic rate of PC3 cells (Fig. 6A, right 
panel) nor incorporation of 3H-thymidine 
(Fig. 6B), while infection of PC3 cells with 
Ad-REIC was confirmed to efficiently 
induce apoptosis in a cell-autonomous 
manner (Fig. 6A, left panel).  
 Involvement of IL-7 in indirect 
tumor-suppressive effect of Ad-REIC. Finally, 
we examined whether IL-7 could mediate 
the indirect tumor-suppressive effect of 
Ad-REIC-infected NHF. Intraperitoneal 
injection of anti-IL-7 antibody (0.5 mg) on 
day 0 and day 4 partially restored the growth 
of PC3 cells transplanted with 
Ad-REIC-infected NHF determined on day 
7 (Fig. 7A). Natural killer (NK)-enriched 
cells isolated from spleens of nude mice 
bearing PC3 cells and Ad-REIC-infected 
NHF showed higher cytotoxicity to PC3 
cells in vitro than did those from mice 
bearing PC3 cells and Ad-LacZ-infected 
NHF, and the elevated cytotoxicity was 
abrogated by injection of anti-IL-7 antibody 
(Fig. 7B). These results indicate that the 
indirect suppressive effect on growth of PC3 
cells by Ad-REIC-infected NHF was at least 
partly due to induction of IL-7. 
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 DISCUSSION 
 
 The initial concept of using tumor 
suppressor genes in cancer gene therapy was 
that their delivery would correct or eradicate 
cancer cells defective in the corresponding 
tumor suppressor genes. The potent 
tumor-specific cell-killing activity of 
Ad-REIC, however, depends on the 
triggering of ER stress and has nothing to do 
with the physiological function of 
REIC/Dkk-3 protein as indicated in the 
present study and our previous studies 
(13,14). An anti-cancer effect via ER stress 
has also been shown in gene therapy using 
mda-7/IL-24 (31). In addition to such 
cell-autonomous killing of cancer cells by 
the induction of ER stress, we showed in the 
present study that ER stress evoked by 
Ad-REIC led to overproduction of IL-7 in 
NHF (Fig. 1).  
 Signal transduction linking ER stress 
to transcriptional activation of IL-7. When 
cells are subjected to ER stress, TRAF2 is 
recruited to IRE1α, a sensor protein of ER 
stress, and TRAF2 in turn activates ASK1 
(21). JNK and p38 are well known 
downstream kinases of ASK1. Infection of 
Ad-REIC resulted in activation of IRE1α 
and  ASK1 in similar manners both in NHF 
and in PC3 cells, but activation of JNK, 
which is an essential step for induction of 
apoptosis in cancer cells by Ad-REIC (13), 
was obsereved in PC3 cells and not in NHF 
(Fig. 2D). This is the critical step 
determining differential sensitivity to 
Ad-REIC between most cancer cells and 
normal cells, but mechanisms of the 
differential activation of MAPKs remain to 
be clarified.  
 ASK1 is thought to play a pivotal role 
in innate immunity in mammals. Activity of 
ASK1 was shown to be essential for 
lipopolysaccharide-induced activation of 
p38, which resulted in induction of 
cytokines, including IL-1β, IL-6, and TNFα, 
in splenic cells, dendritic cells and a 
macrophage cell line (32). 
Lipopolysaccharide acts on a cell surface 
receptor, Toll-like receptor 4. Since ASK1 is 
also activated in cells subjected to ER stress 
(Fig. 2D), it is conceivable that a certain 
immune response is evoked in cells upon ER 
stress. Although the biological significance 
of the ER stress-triggered activation of 
ASK1 is not well understood, it may 
contribute to elimination of pathogens such 
as viruses and bacteria by activating innate 
immunity. ER stress triggered by overload 
with excess viral protein synthesis may lead 
to apoptosis and inflammatory responses, 
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eventually resulting in prevention of further 
spreading of the virus (33). ER stress was 
shown to induce interferon β via XBP-1 in 
macrophages (34). The present finding that 
IL-7 was induced by ER stress and the fact 
that IL-7 plays non-redundant pleiotropic 
roles in development of both B cells and T 
cells, including the development of NK cells 
(22,35), may lead to a better understanding 
of the relevance of ER stress to immune 
response.  
 Indirect tumor suppression by 
Ad-REIC-infected NHF. NHF infected with 
Ad-REIC suppressed the growth of 
untreated PC3 cells transplanted in a mixture 
into nude mice (Fig. 5). Similar suppression 
of tumor growth by Ad-REIC-infected NHF 
was observed in immune-competent 
BALB/c mice into which syngeneic 
Colon26 cells had been transplanted (Fig. 
5C and supplemental Fig. S3C). The indirect 
tumor-suppressive effect was not observed 
in culture (Fig. 6), indicating a host 
cell-mediated mechanism. Cytolytic activity 
of NK cells prepared from nude mice 
transplanted with Ad-REIC-infected NHF 
and PC3 cells was higher than that of NK 
cells prepared after transplantation with 
Ad-LacZ-infected NHF and PC3 cells (Fig. 
7). It is known that athymic nude mice 
lacking development of T cells have higher 
cytotoxic activity of NK cells and 
macrophages than that in their euthymic 
counterparts (36). Injection of an antibody 
against IL-7 largely abrogated the 
suppression of the growth of PC3 cells by 
Ad-REIC-infected NHF as well as cytolytic 
activity of NK cells isolated from the 
transplanted mice (Fig. 7). These results 
indicate that IL-7 overproduced by ER stress 
activates innate immunity involving NK 
cells and eventually leads to suppression of 
tumor growth in vivo. We showed previously 
that a single injection of Ad-REIC into 
tumors formed by transplantation of PC3 
cells into mice resulted in 4 out of 5 mice 
becoming tumor-free (13). This was more 
efficient than had been expected considering 
that the infection efficiency of an adenovirus 
vector cannot be 100% in solid tumors in 
vivo. The efficient therapeutic effect, 
however, is conceivable when Ad-REIC has 
an additional non-cell autonomous 
mechanism for tumor suppression. We also 
showed that intratumoral injection of 
Ad-REIC resulted in suppression of local 
metastasis of a prostate cancer cell line in an 
orthotopic model (37). This may be at least 
in part due to an indirect effect via 
Ad-REIC-infected normal cells in the 
environment surrounding cancer cells. 
 Ad-REIC as a bi-armed therapeutic 
12 
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agent. Although therapeutic trials using IL-7 
against cancer have been carried out since 
the late 1990s, no major clinical responses 
have been reported thus far. This may partly 
be due to advanced stages of the cancer 
cases (30,38,39), and activation of immune 
reaction against cancer by IL-7 might by 
itself be not strong enough to lead to 
massive killing of cancer cells. Our results 
show that the mis-targeted infection of 
cancer stroma cells by Ad-REIC activates 
the immune system through production of 
IL-7, while Ad-REIC infection of cancer 
cells results in a potent selective 
cell-autonomous killing function without 
immune suppression. This "one-bullet 
two-arms" finding may lead to a powerful 
new therapeutic approach to the treatment of 
human cancer. 
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FIGURE LEGENDS 
 
 Fig. 1. Infection with Ad-REIC induced production of IL-7 but not apoptosis in NHF. A. 
Apoptosis induced by infection with Ad-LacZ (L) or Ad-REIC (R) at 20 MOI. B. Forced 
expression of REIC/Dkk-3 in NHF and PC3 cells by Ad-REIC infected at 20 MOI determined 
by Western blot analysis. C. Expression of REIC/Dkk-3 protein over a period of 2 weeks in 
confluent NHF infected with Ad-REIC at 20 MOI. D. Screening for cytokines secreted into 
the medium by NHF infected with Ad-REIC using an antibody array. Dotted square indicates 
antibody against IL-7. E. Induction of IL-7 by Ad-REIC in NHF (24 h) demonstrated by 
Northern blot analysis. F. Production of IL-7 by NHF infected with Ad-REIC in culture. 
Amounts of IL-7 were determined by ELISA contained in the media of NHF uninfected, 
infected with Ad-LacZ, or infected with Ad-REIC at 20 MOI incubated from 24 h to 36 h 
after infection.  
 
 Fig. 2. Signal transduction leading to induction of IL-7 in NHF infected with Ad-REIC. 
A. Induction of IL-7 by Ad-REIC in NHF demonstrated by Northern blot analysis. exREIC, 
exogenously added REIC/Dkk-3 protein purified from a conditioned medium of 
Ad-REIC-infected NHF. B. Induction of IL-7 in NHF by tunicamycin (TM; 5 μg/ml, 24 h) 
demonstrated by Northern blot analysis. C. Induction of IL-7 by TM or Ad-REIC was 
abrogated by down-regulation of a ER stress sensor, IRE1α. siRNAs were added 24 h prior to 
the application with TM or Ad-REIC. D. Western blot analysis for proteins involved in signal 
transduction triggered by Ad-REIC and leading to induction of IL-7. Cells were infected with 
Ad-REIC or Ad-LacZ at 20 MOI for 36 h. E. Western blot analysis for proteins involved in 
signal transduction triggered by 5 μg/ml tunicamycin (TM) in NHF treated for 24 h. F. 
Effects of kinase inhibitors on IL-7 induction. The inhibitors were added 1 h prior to infection 
with Ad-REIC. SB, SB-203580 (p38 inhibitor: 1 μM); SC, SC-68376 (p38 inhibitor: 10 μM); 
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SP, SP600125 (JNK inhibitor: 100 nM); AktI (Akt inhibitor: 10 μM). 
 
 Fig. 3. IRF1 is a critical transacting factor for the induction of IL-7 in NHF infected 
with Ad-REIC. A. Western blot analysis for IRF1 and IRF2 in cells infected with Ad-LacZ or 
Ad-REIC at 20 MOI. B. A pul17-down assay of proteins bound to the IL-7 promoter in vitro 
using a biotinylated genomic fragment (–1345 to -9) of the human IL-7 promoter. Ext., 
nuclear extract. Contaminated tubulin was detected in the nuclear extract but not in the 
precipitates. C. Electromobility shift assay for proteins binding to the human IL-7 promoter 
using nuclear extracts from NHF 36 h after infection. Mut, a mutated probe; white arrowhead, 
shifted bands; black arrowhead, supershifted bands observed with an anti-human IRF-1 or 
IRF-2 antibody. D. Down-regulation of IRF-1 by siRNA. NHF were transfected with 2 
different siRNAs for IRF-1. E. Chromatin immunoprecipitation assay of the IL-7 promoter 
using either IRF-1 antibody or IRF-2 antibody in NHF transfected with siRNA for IRF-1 24 h 
prior to the infection. F. Induction of IL-7 in NHF by Ad-REIC (20 MOI for 36 h) was 
abrogated by down-regulation of IRF-1 using siRNA. 
 
 Fig. 4. STAT1 mediates from p38 to IRF-1 in the signal transduction leading to 
induction of IL-7. A. Effects of kinase inhibitors on proteins involved in signal transduction 
triggered by Ad-REIC. The kinase inhibitors were applied under conditions described in the 
legend for Fig. 2E. P-STAT1 band was detected by an antibody against 
727Ser-phosphorylated STAT1. B. Effect of STAT1 siRNA on proteins involved in signal 
transduction triggered by Ad-REIC. C. Effect of STAT1 siRNA on binding of IRF-1 and 
IRF-2 to the IL-7 promoter demonstrated under conditions similar to those described in the 
legend for Fig. 3E. D. Induction of IL-7 in NHF by Ad-REIC was abrogated by 
down-regulation of STAT1 siRNA. E. Exogenous IL-7 did not induced IL-7 as demonstrated 
by Northern blot analysis. F. Exogenous IL-7 did not activate p38-STAT1-IRF-1 pathway as 
demonstrated by Western blot analysis. G. Signal transduction pathway triggered by Ad-REIC 
leading to the induction of IL-7. 
 
 Fig. 5. Suppression of growth of untreated PC3 cells by co-transplanted NHF infected 
with Ad-REIC. A. Quantitated volume of the tumors formed 14 days after transplantation into 
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nude mice of 5x106 PC3 cells mixed with 5x106 NHF infected with Ad-LacZ or Ad-REIC at 
20 MOI. B. Histology of tumors described in A examined 14 days after transplantation. HE, 
hematoxilin-eosin staining. Cytokeratin K18 (CK18: rabbit anti-human CK18 antibody, 
Abcam, Cambridge, MA) and CD49b (FITC-conjugated rat anti-mouse CD49b antibody, 
Miltenyi Biotec, Auburn, CA) were used for identification of PC3 cells and mouse NK cells, 
respectively. Scale bars in HE-stained panels, 200 μm; scale bars in immunostained panels, 50 
μm. C. Indirect tumor suppressive effect in BALB/c mice. Untreated Colon26 cells (4x106) 
mixed with dermal fibroblasts (4x106) infected with either Ad-LacZ or Ad-REIC at 100 MOI 
were subcutaneously transplanted and the sizes of tumors were determined 7 days after 
transplantation. D. Synergistic tumor suppression due to direct and indirect effects of 
Ad-REIC. NHF (20 MOI) and PC3-luc cells (1 MOI) were infected with either Ad-REIC (R) 
or Ad-LacZ (L). Three million cells of each type were mixed and transplanted into nude mice. 
Observation was carried out with IVIS 2000 after injection of Luciferin 7 and 14 days after 
transplantation.  
 
 Fig. 6. Effect of Ad-REIC and IL-7 on NHF in culture. A. Induction of apoptosis in PC3 
cells in culture by direct infection of Ad-REIC (left panel) or by an indirect effect through the 
infected NHF (right panel). The indirect effect was examined after co-cultivating for 1 week. 
Numbers of cells undergoing apoptosis were estimated among cytokeratin-positive cells only. 
B. DNA synthesis of PC3 incubated with 1 μCi/ml 3H-thymidine for 24 h. Neither IL-7 nor 
REIC/Dkk-3 protein exerted an inhibitory effect on DNA synthesis of PC3 in culture. C. 
Induction of apoptosis by Ad-REIC (20 MOI, 36 h) but not by IL-7 (24 h) in PC3 cells in 
culture. TUNEL-positive cells are shown in green. Scale bars, 50 μm. 
 
 Fig. 7. Involvement of IL-7 in the indirect tumor-suppressive effect of Ad-REIC. A. 
Abrogation of the suppressive effect of Ad-REIC-infected NHF on the growth of PC3 cells in 
vivo by intraperitoneal injection of an antibody against IL-7 (0.5 mg). Transplantation was 
performed under conditions similar to those described in the legend of Fig. 5A. IL-7 antibody 
was injected on day 0 and day 4, and sizes of tumors were determined on day 7. B. 
Cytotoxicity to PC3 cells exerted by NK-enriched spleen cells isolated from the nude mice 
described in the legend of A. 
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